Ocugen CEO to Highlight Gene Therapy Advances at Healthcare Equity Conference

Ocugen

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will engage in a fireside chat at the Emerging Growth Virtual Healthcare Equity Conference, hosted by Noble Capital Markets, from April 17 – 18, 2024. The session is scheduled for Wednesday, April 17, 2024, at 10 a.m. ET and will be streamed live online.

During this event, Dr. Musunuri plans to discuss Ocugen’s latest strides in business and clinical development. A significant focus will be on the FDA’s recent approval for Ocugen to begin a Phase 3 clinical trial of OCU400. This innovative gene therapy aims to treat retinitis pigmentosa (RP), a group of genetic disorders affecting the eyes. Notably, OCU400 represents the first gene therapy for RP to advance to a late-stage trial, targeting a broad indication within this condition.

Interested parties can access a live webcast of the discussion through the Events section of Ocugen’s website. Additionally, the presentation will be part of Channelchek‘s complete catalog, Noble’s investor portal. For those unable to attend the live event, a recording will be archived on Ocugen’s website for 90 days post-conference, ensuring wider accessibility to these critical updates.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.

READ:  Women in Tech SEO Festival Returns to Philadelphia: A Day of Insightful Discussions Await